Catalyst Wire Dossier Catalyst Wire Dossier

Enjaymo

sutimlimab · Recordati Rare Diseases
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Enjaymo, covering 2022-02-04 to 2025-08-01. Get the full timeline:

Most recent: EMA Authorised: Enjaymo (sutimlimab) — Recordati Rare Diseases

See pricing